Answers are grounded in this paper and cite their sources.
Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in patients with severe obesity undergoing metabolic/bariatric surgery. Noninvasive preoperative stratification of histologic liver abnormalities remains incomplete. We evaluated conventional regression models and a separate exploratory machine-learning analysis of MASH grade 1 versus grades 2/3. Methods This retrospective single-center cohort included patients undergoing Roux-en-Y gastric bypass between March 2000 and March 2025. Of 1,350 surgical patients, 745 underwent intraoperative wedge liver biopsy and 375 had complete data for conventional modeling. Conventional endpoints were MASLD-compatible histologic abnormality, any documented fibrosis, and higher-grade steatohepatitis, defined as biopsy-reported grades 2/3. The machine-learning analysis included 284 patients with steatohepatitis and used routine preoperative variables, ultrasound-reported steatosis, NFS, the AST/ALT ratio, and FIB-4. Model development used RandomizedSearchCV and repeated stratified cross-validation within the training set, followed by training-based threshold selection and held-out test evaluation. Results BMI and triglycerides were associated with MASLD-compatible histologic abnormality, BMI with any fibrosis, and age, BMI, triglycerides, and AST with higher-grade steatohepatitis. The latter conventional model had an apparent AUC of 0.737 and a mean cross-validated AUC of 0.692. L2-penalized logistic regression had the highest machine-learning test ROC-AUC point estimate (0.730; 95% CI, 0.585–0.864), with sensitivity 0.739 for MASH grades 2/3 at a threshold of 0.49. Test Brier score was 0.242; calibration was unsatisfactory (ECE 0.203; calibration slope 13.469), and decision-curve findings remained exploratory. Conclusion Routine preoperative information showed moderate discrimination for selected histologic outcomes. Both the conventional score and the machine-learning severity classifier require further validation before clinical implementation.
No takes yet. Share an insight, caveat, or question.
Corrêa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: